These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 28418672)

  • 1. A Liposome Encapsulated Ruthenium Polypyridine Complex as a Theranostic Platform for Triple-Negative Breast Cancer.
    Shen J; Kim HC; Wolfram J; Mu C; Zhang W; Liu H; Xie Y; Mai J; Zhang H; Li Z; Guevara M; Mao ZW; Shen H
    Nano Lett; 2017 May; 17(5):2913-2920. PubMed ID: 28418672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pH-Sensitive Nanocarrier for Tumor Targeting : Delivery of Ruthenium Complex for Tumor Theranostic by pH-Sensitive Nanocapsule.
    Chen L; Fu C; Deng Y; Wu W; Fu A
    Pharm Res; 2016 Dec; 33(12):2989-2998. PubMed ID: 27590630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-cancer effect of series of strained photoactivatable Ru(II) polypyridyl complexes on non-small-cell lung cancer and triple negative breast cancer cells.
    Fayad C; Audi H; Khnayzer RS; Daher CF
    J Biol Inorg Chem; 2021 Feb; 26(1):43-55. PubMed ID: 33221954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The trans-[Ru(PPh
    Becceneri AB; Popolin CP; Plutin AM; Maistro EL; Castellano EE; Batista AA; Cominetti MR
    J Inorg Biochem; 2018 Sep; 186():70-84. PubMed ID: 29857173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymeric Encapsulation of a Ruthenium Polypyridine Complex for Tumor Targeted One- and Two-Photon Photodynamic Therapy.
    Karges J; Li J; Zeng L; Chao H; Gasser G
    ACS Appl Mater Interfaces; 2020 Dec; 12(49):54433-54444. PubMed ID: 33238711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel ruthenium(ii) gallic acid complex disrupts the actin cytoskeleton and inhibits migration, invasion and adhesion of triple negative breast tumor cells.
    Graminha AE; Honorato J; Correa RS; Cominetti MR; Menezes ACS; Batista AA
    Dalton Trans; 2021 Jan; 50(1):323-335. PubMed ID: 33305766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxicity and anti-tumor effects of new ruthenium complexes on triple negative breast cancer cells.
    Popolin CP; Reis JPB; Becceneri AB; Graminha AE; Almeida MAP; Corrêa RS; Colina-Vegas LA; Ellena J; Batista AA; Cominetti MR
    PLoS One; 2017; 12(9):e0183275. PubMed ID: 28898246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Half-sandwich Os(ii) and Ru(ii) bathophenanthroline complexes: anticancer drug candidates with unusual potency and a cellular activity profile in highly invasive triple-negative breast cancer cells.
    Pracharova J; Novohradsky V; Kostrhunova H; Štarha P; Trávníček Z; Kasparkova J; Brabec V
    Dalton Trans; 2018 Sep; 47(35):12197-12208. PubMed ID: 30112527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A photoactivatable Ru (II) complex bearing 2,9-diphenyl-1,10-phenanthroline: A potent chemotherapeutic drug inducing apoptosis in triple negative human breast adenocarcinoma cells.
    Mansour N; Bodman-Smith K; Khnayzer RS; Daher CF
    Chem Biol Interact; 2021 Feb; 336():109317. PubMed ID: 33197429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ruthenium complex delivery using liposomes to improve bioactivity against HeLa cells via the mitochondrial pathway.
    Guo B; Liao C; Fang Y; Li S; Li X; Lu Z; Chen Y
    Nanomedicine (Lond); 2018 Nov; 13(22):2851-2866. PubMed ID: 30457036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carbosilane ruthenium metallodendrimer as alternative anti-cancer drug carrier in triple negative breast cancer mouse model: A preliminary study.
    Michlewska S; Maly M; Wójkowska D; Karolczak K; Skiba E; Hołota M; Kubczak M; Ortega P; Watala C; Javier de la Mata F; Bryszewska M; Ionov M
    Int J Pharm; 2023 Apr; 636():122784. PubMed ID: 36858135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. On the Cytotoxicity of Chiral Ruthenium Complexes Containing Sulfur Amino Acids against Breast Tumor Cells (MDA-231 and MCF-7).
    Leite CM; de Araujo-Neto JH; Corrêa RS; Colina-Vegas L; Martínez-Otero D; Martins PR; Silva CG; Batista AA
    Anticancer Agents Med Chem; 2021; 21(9):1172-1182. PubMed ID: 32838726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panitumumab-DOTA-
    Facca VJ; Cai Z; Gopal NEK; Reilly RM
    Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring cellular uptake, accumulation and mechanism of action of a cationic Ru-based nanosystem in human preclinical models of breast cancer.
    Piccolo M; Misso G; Ferraro MG; Riccardi C; Capuozzo A; Zarone MR; Maione F; Trifuoggi M; Stiuso P; D'Errico G; Caraglia M; Paduano L; Montesarchio D; Irace C; Santamaria R
    Sci Rep; 2019 May; 9(1):7006. PubMed ID: 31065032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoencapsulation of Ruthenium Complex Ru(ThySMet): A Strategy to Improve Selective Cytotoxicity against Breast Tumor Cells in 2D and 3D Culture Models.
    Becceneri AB; Fuzer AM; Lopes AC; da Silva PB; Plutin AM; Batista AA; Chorilli M; Cominetti MR
    Curr Drug Discov Technol; 2024; 21(2):e060623217687. PubMed ID: 37282638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
    Nhukeaw T; Temboot P; Hansongnern K; Ratanaphan A
    BMC Cancer; 2014 Feb; 14():73. PubMed ID: 24507701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transport of the Ruthenium Complex [Ru(GA)(dppe)
    Naves MA; Graminha AE; Vegas LC; Luna-Dulcey L; Honorato J; Menezes ACS; Batista AA; Cominetti MR
    Mol Pharm; 2019 Mar; 16(3):1167-1183. PubMed ID: 30633527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, Structure and Cytotoxicity of N,N and N,O-Coordinated Ru
    Mukherjee A; Koley TS; Chakraborty A; Purkait K; Mukherjee A
    Chem Asian J; 2021 Nov; 16(22):3729-3742. PubMed ID: 34549886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterobimetallic Ru(ii)/Fe(ii) complexes as potent anticancer agents against breast cancer cells, inducing apoptosis through multiple targets.
    Guedes APM; Mello-Andrade F; Pires WC; de Sousa MAM; da Silva PFF; de Camargo MS; Gemeiner H; Amauri MA; Gomes Cardoso C; de Melo Reis PR; Silveira-Lacerda EP; Batista AA
    Metallomics; 2020 Apr; 12(4):547-561. PubMed ID: 32108850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ruthenium(II) polypyridyl complexes: cellular uptake, cell image and apoptosis of HeLa cancer cells induced by double targets.
    Yu Q; Liu Y; Xu L; Zheng C; Le F; Qin X; Liu Y; Liu J
    Eur J Med Chem; 2014 Jul; 82():82-95. PubMed ID: 24878637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.